TBX3 and neoplasm: The IMvigor210 cohort, the largest BLCA immunotherapy cohort reported, indicated that TBX3 expression was significantly higher in patients with a desert immune phenotype (Figure 8G), low PD-L1 expression on tumor cells (TC0) (Figure 8H), and low PD-L1 expression on immune cells (IC0) (Figure 8I).